Table 2.
Clinical and biological COVID-19 symptoms at admission and during follow-up
| COVID-19 symptoms | At diagnosis | During follow-up |
|---|---|---|
| (n = 21) | (n = 21) | |
| Clinical symptoms, n (%) | ||
| No symptoms | 5 (23.8) | 1 (4.8) |
| Fever >38° | 9 (42.9) | 13 (61.9) |
| Cough | 13 (61.9) | 17 (81) |
| Dyspnoea requiring oxygen | 9 (42.9) | 12 (57.1) |
| Sore throat | 5 (23.8) | 8 (38.1) |
| Confusion | 0 (0) | 1 (4.8) |
| Headache | 3 (14.3) | 3 (14.3) |
| Myalgia | 3 (14.3) | 5 (23.8) |
| Diarrhoea | 3 (14.3) | 3 (14.3) |
| Nausea or vomiting | 1 (4.8) | 4 (19.0) |
| Anosmia or ageusia | 0 (0) | 2 (9.5) |
| Biological parameters, n (%) | ||
| Leucopaenia (WBC <4 g/L) | 14 (66.7) | 17 (81.0) |
| Anaemia (haemoglobin <100 g/L) | 5 (23.8) | 17 (81.0) |
| Lymphopaenia (lymphocytes <1.0 g/L) | 13 (61.9) | 17 (81.0) |
| Thrombopaenia (platelets <150 g/L) | 13 (61.9) | 14 (66.7) |
| Ferritin >800 ng/mL | 11 (55) | 16 (80.0) |
| C-reactive protein >10 mg/L | 18 (85.7) | 19 (90.5) |
| Procalcitonin >0.25 ng/mL | 18 (90.0) | 20 (95.2) |
| Abnormal hepatic enzymes (ASAT or ALAT >2× NV) | 1 (4.8) | 3 (14.3) |
| Myocarditis (troponin T >50 pg/mL) | 15 (71.4) | 18 (85.7) |
| Number of days with need for oxygen, mean ± SD | – | 4.0 ± 4.9 |
| Number of days with fever ≥38°C, mean ± SD | – | 1.5 ± 2.0 |
ASAT, aspartate aminotransferase; ALAT, alanine aminotransferase; NV, normal value.